Eastern Biotech in Dubai is now offering BGI Health's non-invasive sequencing-based prenatal test for Down syndrome under the name Trigene. The test, which BGI calls NIFTY for noninvasive fetal trisomy, is based on a shotgun sequencing strategy.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
An opinion piece appearing in Newsday likens familial DNA search to stop-and-frisk policies.
The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.
In Nature this week: genotypes linked to hip osteoarthritis, and more.
Startup companies are taking on personalized medicine, CNET reports.
Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.
In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay.
This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.
This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.